Press Releases Ypsomed Group

Burgdorf - In the 2004/05 business year Ypsomed achieved new highs in terms of sales, profit and investments. The Ypsomed Group's consolidated sales rose 21.7% to CHF 241.8 million. In the core business (pen systems, pen needles and Ypsotec) sales even increased by 42.8%. Particularly pleasing was a 157.8% rise in operating profit to CHF 47.5 million, representing an operating profit margin of 19.7%.

Burgdorf - Ypsomed AG in collaboration with Safety Syringes, Inc. has designed a reusable Autoinjector specifically for use with the UltraSafe Drug Delivery Systems by Safety Syringes, Inc.

Press Releases Ypsomed Group

Burgdorf - Ypsomed, the leading independent developer and manufacturer of custom-made injection pens for pharmaceutical and biotech companies, and one of the leading suppliers of pen needles, is focusing future investments on its core business.

Press Releases Ypsomed Group

Burgdorf - OptiClik, developed and manufactured by Ypsomed, is the first "semi-disposable" insulin pen-system now launched by Sanofi-Aventis for its long-acting insulin Lantus in the US market. The market launch of OptiClik is a major milestone within Ypsomed's growth strategy.

Press Releases Ypsomed Group

Burgdorf-The offering of shares in Ypsomed Holding AG attracted high investor interest and was 7.6 times covered. The issue price for one registered share in Ypsomed Holding AG was set at CHF 68.00. Shares will be trading on the SWX Swiss Exchange for the first time today.